<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Focal segmental glomerulosclerosis: Genetic causes</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Focal segmental glomerulosclerosis: Genetic causes</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Focal segmental glomerulosclerosis: Genetic causes</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sanjeev Sethi, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rasheed A Gbadegesin, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brad H Rovin, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1684784751"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Focal segmental glomerulosclerosis (FSGS) is a morphologic pattern of glomerular injury primarily directed at the glomerular visceral epithelial cell (the podocyte) and defined by the presence of sclerosis in parts (segmental) of some (focal) glomeruli by light microscopy of a kidney biopsy specimen. The lesion of FSGS can be classified into primary, secondary, genetic, and undetermined forms using a clinicopathologic approach. This classification step is crucial for determining appropriate therapy; identification of an FSGS lesion solely by light microscopy is never sufficient for management decisions. The lesion of FSGS is distinct from focal and global glomerulosclerosis, which has a different prognosis and treatment.</p><p>This topic will review the genetic causes of FSGS. The epidemiology, classification, pathogenesis, clinical features, diagnosis, and treatment of FSGS and recurrent disease in the kidney transplant are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>.)</p><p></p><p class="headingAnchor" id="H2191321679"><span class="h1">EPIDEMIOLOGY OF GENETIC FSGS</span><span class="headingEndMark"> — </span>The prevalence of genetic FSGS varies widely depending upon the population being studied [<a href="#rid1">1-4</a>]. In regions of the world where consanguinity is prevalent, for example, the prevalence of genetic FSGS among all patients with FSGS may be as high as 30 percent, whereas in the outbred population, the prevalence may be as low as &lt;5 percent. The existence of founder mutations in a particular population may also affect prevalence rates. As an example, the prevalence of genetic FSGS in central Europe is generally higher than in the United States because of different founder mutations in the podocin (<em>NPHS2</em>) gene [<a href="#rid3">3</a>]. Overall, the prevalence of monogenic FSGS is estimated to be approximately 30 to 50 percent among patients with genetic/familial disease and 5 to 30 percent in sporadic FSGS.</p><p>The prevalence of genetic FSGS may also depend upon the age of onset of disease. In a European cohort study of 89 children from 80 families with the nephrotic syndrome manifesting in the first year of life, 85 percent of families with a disease onset before three months of age were found to have a known FSGS mutation, compared with 44 percent of families with a disease onset between 4 and 12 months of age [<a href="#rid5">5</a>].</p><p>Familial disease may account for a significant proportion of patients with glucocorticoid-resistant FSGS, particularly children [<a href="#rid6">6,7</a>]. In a large cohort study from the steroid-resistant nephrotic syndrome (SRNS) study group, 2016 patients from 1783 unrelated families were screened for mutations in 27 genes associated with glucocorticoid-resistant FSGS [<a href="#rid2">2</a>]. Mutations were found in 50 percent of infantile-onset cases (age 4 to 12 months), 25 percent of early childhood-onset cases (age 13 months to 6 years), 18 percent of late childhood-onset cases (age 6 to 12 years), and 11 percent of adolescent-onset cases (age 13 to 18 years). A monogenic form of FSGS accounted for 21 percent of the patients with SRNS with onset between 19 and 25 years of age.</p><p>The prevalence of genetic adult-onset FSGS is difficult to infer due to the paucity of large studies in this population [<a href="#rid8">8</a>]. Patients with adult-onset genetic FSGS without a known family history of kidney disease have been described, and the lack of family history may be due to the fact that many of the mutations associated with FSGS have an incomplete penetrance [<a href="#rid9">9,10</a>]. In one study of 193 adults with FSGS (43 with familial FSGS, 150 with sporadic FSGS), genetic testing by whole-exome sequencing yielded a diagnosis of genetic FSGS in 28 percent of patients with familial disease and 8 percent of those with sporadic disease, for an overall genetic diagnostic rate of 11 percent [<a href="#rid10">10</a>]. However, the prevalence of genetic FSGS in this cohort may be an underestimate of the actual prevalence among adults with FSGS. Among the 82 patients who were treated with immunosuppression and for whom treatment response was known, 45 and 29 percent achieved a partial or complete remission, respectively; none of the patients with a genetic mutation achieved complete remissions. These findings suggest that the study population may have included a significant proportion of patients with primary FSGS who would not be expected to have a genetic mutation. Another study in 24 adults with a high likelihood of having genetic FSGS identified a disease-causing variant in 7 (29 percent) [<a href="#rid11">11</a>]. </p><p class="headingAnchor" id="H3056180805"><span class="h1">CLINICAL PRESENTATION</span><span class="headingEndMark"> — </span>Genetic forms of FSGS presenting in infancy or childhood typically present with full nephrotic syndrome and widespread foot process effacement on electron microscopy (EM). However, the clinical and histologic phenotype of adult-onset genetic FSGS is widely variable and rarely specific, with the same mutations showing different morphologic features on both light microscopy (LM) and EM [<a href="#rid9">9</a>]. These issues, as well as clinical features associated with specific FSGS gene mutations, are discussed in more detail elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Classification and clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Pathology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See <a class="local">'Genes known to cause FSGS'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Genetic variants'</a>.)</p><p></p><p>Findings suggestive, but not diagnostic, of familial FSGS include a family history of FSGS and disease onset in infancy or early childhood [<a href="#rid12">12</a>]. Thus, a detailed family history is of paramount importance in the evaluation of such patients.</p><p>Glucocorticoid resistance is a consistent finding in patients with genetic FSGS [<a href="#rid13">13-16</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Classification and clinical features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p></p><p class="headingAnchor" id="H327258824"><span class="h1">GENETIC TESTING FOR FSGS</span></p><p class="headingAnchor" id="H4027496936"><span class="h2">Indications for genetic testing</span><span class="headingEndMark"> — </span>The decision to obtain genetic testing depends upon the clinical presentation of the patient and the genetic architecture of disease in the population where the clinician is practicing. Commercial tests are available to detect mutations in over 80 FSGS genes or to sequence the entire genome (whole-genome sequencing) or entire coding regions (whole-exome sequencing). The use of genetic testing in the evaluation of adult patients presenting with a documented FSGS lesion on kidney biopsy and pediatric patients with glucocorticoid-resistant idiopathic nephrotic syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Differentiating between primary, secondary, and genetic FSGS'</a> and  <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Management", section on 'Genetic testing'</a>.)</p><p>While one can make a case for more permissive testing in regions of the world where consanguinity is high or in regions of the world where there is a particular founder mutation, the same approach will not apply to the outbred population where the prevalence of mutation is likely to be low. In general, the likelihood of positive genetic testing is high in the following groups of patients:</p><p class="bulletIndent1"><span class="glyph">●</span>Pediatric patients with therapy-resistant FSGS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Adult and pediatric patients with a documented FSGS lesion and a family history of chronic kidney disease (especially with proteinuria and/or hematuria). The pattern of inheritance (eg, autosomal dominant, autosomal recessive, X-linked, matrilineal) may help to guide genetic testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with a documented FSGS lesion and a syndromic presentation (eg, skin lesions, deafness, neurologic abnormalities, ocular abnormalities, skeletal abnormalities, maturity onset diabetes of the young, hepatosplenomegaly, metabolic acidosis).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with FSGS of undetermined cause in whom the clinical presentation and pathologic features are discordant (eg, absence of nephrotic syndrome but widespread foot process effacement on electron microscopy [EM]) [<a href="#rid17">17</a>].</p><p></p><p>Proper selection of patients appears to increase the rate of positive genetic testing. In a study of 49 patients aged 18 years and older with an FSGS lesion on kidney biopsy, the overall rate of detection of a monogenic cause was 43 percent [<a href="#rid17">17</a>]. Individuals with FSGS of undetermined cause had the highest positive test rate (88 percent), followed by those with secondary FSGS without an identifiable cause (62 percent) and those with secondary FSGS with a known cause (33 percent). Univariate analysis showed that family history of kidney disease (odds ratio [OR] 13.8), absence of nephrotic syndrome (OR 8.2), and female sex (OR 5.1) were strong predictors of finding a causative genetic variant in the entire cohort. Most individuals with FSGS of undetermined cause in whom the clinical presentation and pathologic features were discordant (eg, absence of nephrotic syndrome but widespread foot process effacement on EM, or nephrotic syndrome with segmental foot process effacement) had a genetic diagnosis.</p><p class="headingAnchor" id="H1662966595"><span class="h2">Methods for genetic testing</span><span class="headingEndMark"> — </span>The most common genetic testing methods used by clinicians and commercial laboratories are direct (Sanger) sequencing and targeted sequencing by NGS. As there are more than 80 known FSGS genes, targeted NGS is likely to be more practical and comprehensive. In areas where there is a founder effect for a particular mutation (eg, <em>NPHS2</em> in Europe), some clinicians will screen for mutations in these particular genes first before screening for mutations in the entire panel. Some commercial entities are now offering clinical WES for the diagnosis of genetic FSGS. The exome is the coding region of the genome, and it accounts for only 1 percent of the entire human genome. The advantage of WES is that it is all inclusive and mutations may be detected in both candidate and novel genes. However, WES is more expensive than targeted sequencing, and it is more likely to identify multiple variants of unknown significance, especially in the absence of an informative pedigree.</p><p class="headingAnchor" id="H604462841"><span class="h1">CLINICAL IMPLICATIONS OF GENETIC FSGS</span><span class="headingEndMark"> — </span>The identification of a causal mutation in a patient with FSGS will help to establish a firm diagnosis and should inform the approach to therapy and plans for future kidney transplantation. It should be noted, however, that a negative result on genetic testing (no mutation) does not completely rule out genetic FSGS, as the patient may have a mutation in a yet-to-be-discovered novel gene. In general, identification of a genetic cause of FSGS should lead to:</p><p class="bulletIndent1"><span class="glyph">●</span>Extensive discussion with the patient's family that immunosuppression is generally <strong>not</strong> indicated given the low likelihood of response to this therapy, and the use of such agents is not justified. Exceptions include cases with mutations in <em>WT1</em>, <em>TRPC6</em>, <em>PLCE1</em>, <em>MAGIC2</em>, <em>TNS2</em>, <em>DLC1</em>, <em>CKD20</em>, <em>ITSN1</em>, and<em> ITSN2 </em>genes that may respond to immunosuppression [<a href="#rid18">18-20</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children", section on 'Initial therapy'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Management", section on 'Immunosuppressive therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Low threshold for discontinuing immunosuppression if the patient has already been started on immunosuppressive therapy and is not responding to treatment. As an example, therapy could be discontinued in an adult patient who has been unresponsive to treatment with glucocorticoids for six weeks. The same approach should be applied to calcineurin inhibitors and other immunosuppressive agents.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identification of targeted therapies based on the type of mutations. It is known, for example, that some patients with mutations in <em>COQ6</em>, <em>COQ2</em>, and <em>COQ8B</em> may respond to CoQ10 replacement therapy [<a href="#rid21">21-23</a>]. (See  <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Specific gene variants'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prediction of posttransplant disease recurrence. As an example, the risk of FSGS recurrence in patients with primary FSGS is approximately 30 to 70 percent, depending upon how cases are selected, compared with 0 to 8 percent in patients with genetic FSGS [<a href="#rid24">24-26</a>]. The mechanisms underlying posttransplant recurrence of genetic FSGS are not well defined. Circulating anti-nephrin antibodies may play a pathogenic role in the development of recurrent FSGS in patients with mutations in <em>NPHS1</em> but not <em>NPHS2</em> [<a href="#rid14">14,27-29</a>]. (See  <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney", section on 'Pathogenesis'</a>.)</p><p></p><p class="headingAnchor" id="H1610461569"><span class="h1">GENES KNOWN TO CAUSE FSGS</span><span class="headingEndMark"> — </span>A number of genetic forms of FSGS have been described [<a href="#rid10">10,12,30-38</a>] and may account for a significant proportion of patients with glucocorticoid-resistant disease (<a class="graphic graphic_table graphicRef118938" href="/z/d/graphic/118938.html" rel="external">table 1</a>) [<a href="#rid15">15,39</a>]. In general, the genes involved encode for proteins that are integral for proper function of the components of the glomerular filtration barrier (podocytes, glomerular basement membrane [GBM], and the fenestrated capillary endothelium).</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3091.html" rel="external">"Biology of glomerular podocytes"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology"</a>.)</p><p></p><p>The majority of the genetic causes of FSGS in children follow an autosomal recessive pattern of inheritance and manifest in the first year of life, with mutations in the genes for nephrin (<em>NPHS1</em>), podocin (<em>NPHS2</em>), and phospholipase C epsilon 1 (<em>PLCE1</em>) being the most common. Autosomal recessive disease is usually completely penetrant with only very rare cases of asymptomatic individuals.</p><p>Autosomal dominant causes of FSGS are more common in older children, adolescents, and adults. The most common single-gene cause of autosomal dominant FSGS is a mutation in the gene inverted formin, FH2 and WH2 domain containing (<em>INF2</em>), which is responsible for 12 to 17 percent of all cases of autosomal dominant FSGS [<a href="#rid6">6,7,40,41</a>]. Other major genes implicated in autosomal dominant FSGS include actinin alpha 4 (<em>ACTN4</em>), <em>TRPC6</em>, <em>WT1</em>, and <em>LMX1B</em> [<a href="#rid5">5,42</a>].</p><p>Unlike autosomal recessive disease, autosomal dominant disease may be incompletely penetrant, and it is not unusual to have family members with a mutation but no disease phenotype. Thus, kidney transplantation from family members should be handled cautiously, and there is a strong case for screening for the mutation found in the patient before accepting family members as kidney donors. </p><p>Although a matrilineal inheritance pattern of FSGS suggests a mitochondrial gene mutation (which will not be detected by genomic analysis), the trait can also be inherited from the maternal side in an X-linked or autosomal dominant fashion.</p><p class="headingAnchor" id="H951987597"><span class="h2"><i>NPHS1</i> gene</span><span class="headingEndMark"> — </span>Mutations in the gene for nephrin, called <em>NPHS1</em>, cause congenital nephrotic syndrome of Finnish type. (See  <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome of Finnish type'</a>.)</p><p><em>NPHS1</em> mutations have also been identified in older children with steroid-resistant nephrotic syndrome (SRNS) [<a href="#rid43">43,44</a>] and in at least one adult who presented with FSGS at age 27 years [<a href="#rid44">44</a>]. This patient was identified as part of a study in which 97 patients from 89 unrelated families with SRNS and/or FSGS on biopsy were screened by direct DNA sequencing. Compound heterozygous or homozygous <em>NPHS1</em> mutations were detected in five familial and seven sporadic cases of FSGS, including the adult patient described above, and four children ages eight months, one year, six years, and seven years; two of the children were from the same family. The detection rate of <em>NPHS1</em> mutations was 38 percent (5 of 13) among familial cases and 10 percent (7 of 76) among sporadic cases. There were also two patients ages 27 and 29 years who had single <em>NPHS1</em> variants of unknown effect.</p><p class="headingAnchor" id="H1523670232"><span class="h2"><i>NPHS2 </i>gene</span><span class="headingEndMark"> — </span>The causative gene for an autosomal recessive form of familial FSGS was cloned using a positional cloning technique directed at the chromosomal area 1q25-31 [<a href="#rid36">36,45</a>]. This gene, called <em>NPHS2</em>, encodes podocin, which is found exclusively in glomerular podocytes. Patients with FSGS due to mutations in <em>NPHS2</em> usually present with early-onset nephrotic syndrome (age six years or less). (See  <a class="medical medical_review" href="/z/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome and NPHS2 variants'</a>.)</p><p>However, some affected patients have milder disease and present in adolescence or young adulthood; this is found usually in patients with some hypomorphic mutations and also in the common R229Q variants inherited in combination with trans-associated mutation in the N-terminal region of the gene [<a href="#rid46">46</a>]. This was shown in a study of 30 families with apparent autosomal recessive, late-onset FSGS (with an average age of onset of 21 years) and 91 individuals with nonfamilial or sporadic, primary FSGS [<a href="#rid47">47</a>]. Mutations in <em>NPHS2</em> cosegregated with the disease in nine families, while no likely disease-causing mutations were observed in 21. In addition, mutations in both <em>NPHS2</em> alleles have been described in approximately 10 to 25 percent of cases of apparently sporadic, glucocorticoid-resistant FSGS in children from Europe and the Middle East. (See  <a class="medical medical_review" href="/z/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p>Although one might expect that patients with <em>NPHS2</em> mutations would not develop recurrent disease in the transplant, recurrence has been described [<a href="#rid14">14,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>.)</p><p class="headingAnchor" id="H156196654"><span class="h2"><i>ACTN4</i> gene</span><span class="headingEndMark"> — </span>Mutations in the actinin alpha 4 gene (<em>ACTN4</em>) on chromosome 19q13 are associated with an autosomal dominant form of the disease [<a href="#rid34">34,48</a>]. The mutant form of actinin alpha 4 binds to actin more strongly than the wild-type protein, suggesting that the disease might be due to an alteration in the actin cytoskeleton of the glomerular podocytes.</p><p>FSGS resulting from mutations in the actinin alpha 4 gene may be associated with unique ultrastructural features on kidney biopsy. In one study of five patients with actinin alpha 4 mutations, electron-dense podocyte aggregates were observed in all kidney biopsies, while a segmental and irregular immunofluorescent pattern for actinin alpha 4 was noted in the four biopsies available for staining [<a href="#rid49">49</a>]. These observations were not found in the biopsies from patients with FSGS not due to an abnormal actinin alpha 4 gene. Although intriguing, further study in a larger number of patients is required to better characterize these findings.</p><p class="headingAnchor" id="H3794527280"><span class="h2"><i>TRPC6</i> gene</span><span class="headingEndMark"> — </span>As previously mentioned, chromosome 11 harbors a suspect genetic locus for FSGS, which is also the location for the gene for the canonical transient receptor potential cation channel subfamily C member 6 (<em>TRPC6</em>) ion channel. This receptor is expressed in podocytes and is a member of a family of calcium-permeable cation channels. <em>TRPC6</em> also colocalizes to the slit diaphragm with nephrin, podocin, and <em>CD2AP</em>; in addition, alterations in <em>TRPC6</em> calcium currents appear to underlie proper podocyte structure and function [<a href="#rid50">50</a>].</p><p>These features pointed toward defects in the <em>TRPC6</em> gene as a cause of familial FSGS. <em>TRPC6</em> mutations have now been documented in individuals with both familial and nonfamilial FSGS [<a href="#rid50">50-52</a>]. In a study of 71 families with FSGS, mutations in the <em>TRPC6</em> gene segregated with FSGS in five families with autosomal dominant disease [<a href="#rid50">50</a>]. Mutation analysis in 130 patients from 115 families identified <em>TRPC6</em> mutations in two patients with nonfamilial FSGS and one with familial disease [<a href="#rid52">52</a>].</p><p>FSGS-associated <em>TRPC6 </em>mutations have been shown to constitutively activate the calcineurin-nuclear factor of activated T cells (NFAT) pathway, and this effect can be blocked by calcineurin inhibitors [<a href="#rid53">53</a>]. Additional studies are needed to investigate the role of calcineurin inhibitors in the treatment of <em>TRPC6</em>-associated FSGS.</p><p class="headingAnchor" id="H1061905120"><span class="h2"><i>INF2</i> gene</span><span class="headingEndMark"> — </span>Mutations of the <em>INF2</em> gene, which encodes a member of the formin family of actin-regulating proteins, were initially identified in two large families with autosomal dominant FSGS [<a href="#rid40">40</a>]. Similar <em>INF2</em> mutations were subsequently detected in nine additional probands with familial FSGS and shown to be present in affected family members (with biopsy-proven FSGS, end-stage kidney disease [ESKD], or significant proteinuria without another cause) but not in control individuals who had no features of proteinuric kidney disease. In a subsequent study, <em>INF2</em> mutations were identified in 28 of 78 patients (17 percent) with known autosomal dominant FSGS but in only 1 of 84 patients with sporadic FSGS [<a href="#rid41">41</a>].</p><p>Patients with <em>INF2</em>-associated FSGS present at a later age (adolescence or early adulthood) compared with those who have FSGS caused by <em>NPHS1</em> and <em>NPHS2</em> mutations, who typically present at a very early age. (See <a class="local">'NPHS1 gene'</a> above and <a class="local">'NPHS2 gene'</a> above.)</p><p class="headingAnchor" id="H529231881"><span class="h2">Collagen type IV alpha 3, 4, and 5 genes</span><span class="headingEndMark"> — </span>Mutations in the type IV collagen genes known to cause Alport syndrome and thin basement membrane nephropathy (<em>COL4A3</em>, <em>COL4A4</em>, and <em>COL4A5</em>) may be common in patients with familial or sporadic FSGS. Studies have reported prevalence rates of up to 38 percent and 3 percent among cohorts of patients with familial and sporadic FSGS, respectively [<a href="#rid54">54-56</a>].</p><p>Several studies have found that patients with FSGS associated with <em>COL4A</em> mutations frequently do not have clinical or histological features of Alport syndrome [<a href="#rid54">54-57</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In one study of 70 families with a diagnosis of hereditary FSGS, seven (10 percent) were found to have novel variants in <em>COL4A3 </em>or <em>COL4A4 </em>[<a href="#rid54">54</a>]. The predominant clinical finding at the time of diagnosis was proteinuria associated with hematuria. All seven families had individuals with nephrotic-range proteinuria and histologic features of FSGS on kidney biopsy. Electron microscopy (EM) data, which were available for five of the seven families, revealed thin GBMs in only one family; four other families had variable findings that were not consistent with Alport syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another study, 81 patients with FSGS (12 with familial FSGS) were screened for mutations in 39 genes implicated in FSGS; pathogenic mutations were identified in 10 (12 percent) [<a href="#rid55">55</a>]. Eight patients were found to have disease-causing mutations in<em> COL4A3, COL4A4, </em>or <em>COL4A5</em>; only one patient was suspected to have Alport syndrome. All patients had nephrotic-range proteinuria, and one presented with nephrotic syndrome. Although microscopic hematuria was present in the majority (63 percent) of patients, only one patient had hearing loss at presentation. EM showed GBM thickening, fraying, and lamellation characteristic of Alport syndrome in only one patient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study of 193 adult patients with FSGS (43 with familial FSGS, 150 with sporadic FSGS) who underwent genetic testing by whole-exome sequencing, pathogenic variants in <em>COL4A3</em>, <em>COL4A4</em>, or <em>COL4A5</em> were identified in 11 of 20 (55 percent) patients with a genetic cause of FSGS [<a href="#rid10">10</a>]. Among those with <em>COL4A </em>pathogenic variants, the mean age of disease onset was 36 years (range 29 to 42 years), and nearly one-half of the patients (46 percent) developed ESKD at a mean age of 58 years. Of the nine patients who had an available kidney biopsy, five had evidence of GBM abnormalities and all had &gt;50 percent foot process effacement on EM.</p><p></p><p>These data support the need to include <em>COL4A3, COL4A4, </em>and <em>COL4A5 </em>in genetic testing panels for FSGS. Patients with <em>COL4A </em>mutations associated with FSGS may not be clinically suspected of having Alport syndrome and, therefore, are unlikely to otherwise be screened for <em>COL4A </em>mutations. It is unclear if these cases represent phenocopy (ie, an individual displays features characteristic of a genotype other than its own that are produced by environmental rather than genetic factors) or true podocytopathy. One study found that FSGS was the most common misdiagnosis in female patients with X-linked Alport syndrome [<a href="#rid58">58</a>].</p><p class="headingAnchor" id="H1641069317"><span class="h2">Other genes</span><span class="headingEndMark"> — </span>CD2AP is a glomerular protein found at the slit diaphragm. Mutations in the gene for <em>CD2AP</em> have been described in two patients with primary FSGS [<a href="#rid59">59</a>]. Although mutations in <em>LMX1B</em> are usually associated with nail-patella syndrome, some produce FSGS without any apparent extrarenal manifestations [<a href="#rid60">60</a>]. (See  <a class="medical medical_review" href="/z/d/html/6116.html" rel="external">"Nail-patella syndrome", section on 'Pathogenesis and LMX1B gene mutations'</a>.)</p><p>Other genetic disorders are also associated with FSGS on kidney biopsy as well as other renal and/or extrarenal lesions. These include Fabry disease, Alport syndrome, adult-onset cystinosis, nail-patella syndrome, Denys-Drash syndrome, Frasier syndrome, Charcot-Marie-Tooth disease, and glucose-6-phosphatase deficiency. These disorders are discussed in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7195.html" rel="external">"Fabry disease: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6086.html" rel="external">"Genetics, pathogenesis, and pathology of Alport syndrome (hereditary nephritis)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6139.html" rel="external">"Cystinosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/6116.html" rel="external">"Nail-patella syndrome"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2946.html" rel="external">"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)", section on 'Kidney disease'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/118045.html" rel="external">"Causes of differences of sex development", section on 'Global defects in testicular function'</a>.)</p><p></p><p class="headingAnchor" id="H2671905088"><span class="h1">FSGS IN BLACK PATIENTS</span><span class="headingEndMark"> — </span>The relative frequency of the different causes of nephrotic proteinuria varies with race, with the largest difference between Black patients and White patients being the frequency of FSGS. (See  <a class="medical medical_review" href="/z/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p>Among patients with nephrotic proteinuria, two studies from the United States found that Black patients had a higher prevalence of FSGS than White patients, an effect that may be increasing over time. The following observations were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>In a series of 358 adults who underwent kidney biopsy for nephrotic syndrome between 1976 and 1979 and between 1995 and 1997, the frequency of FSGS as the cause was two to three times higher in Black patients compared with White patients in both time periods and increased to a similar degree in both Black patients and White patients from the earlier to the later time period [<a href="#rid61">61</a>]. Between 1995 and 1997, FSGS accounted for more than 50 percent of cases of unexplained nephrotic syndrome in Black adults and for more than 67 percent in Black adults younger than 45 years. There were only seven cases of collapsing FSGS, making it unlikely that the increase in prevalence was due to HIV infection.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a report of 340 patients who underwent kidney biopsy (mean age 43 years) for nephrotic-range proteinuria over a 20-year period from 1975 to 1994, FSGS accounted for 57 percent of cases in Black patients and 23 percent in White patients [<a href="#rid62">62</a>]. Furthermore, the prevalence of FSGS in Black patients increased significantly from 39 percent in 1975 to 1984 to 64 percent in 1985 to 1994. The distribution did not vary with sex or age.</p><p></p><p>None of the above series described biopsy findings in Black patients who had proteinuria &lt;3.5 g/24 hours or absence of nephrotic syndrome. Similarly, electron microscopy (EM) findings were not reported.</p><p>Black patients also account for the overwhelming majority of patients with HIV-associated FSGS (88 percent in a report from the United States Renal Data System [USRDS]) [<a href="#rid63">63</a>]. In addition, Black patients with this disorder have an increased incidence of a family history of end-stage kidney disease (ESKD). This was illustrated in a study that compared 201 Black patients with HIV-associated collapsing FSGS with a control group of 50 HIV-infected Black patients without kidney disease [<a href="#rid64">64</a>]. The patients with FSGS had a much higher percentage of first- and second-degree relatives with ESKD (24 versus 6 percent). (See  <a class="medical medical_review" href="/z/d/html/14026.html" rel="external">"HIV-associated nephropathy (HIVAN)"</a>.)</p><p>The kidney disease in Black patients with nephrotic syndrome and FSGS is clinically and histologically distinct from the kidney disease in the great majority of hypertensive Black patients who have subnephrotic proteinuria and focal <strong>global</strong> glomerulosclerosis (FGGS) rather than focal segmental glomerulosclerosis (FSGS) [<a href="#rid65">65,66</a>]. In patients with FGGS, EM often reveals only segmental foot process effacement, in contrast with the widespread foot process effacement seen in Black patients with HIV-associated collapsing FSGS.</p><p class="headingAnchor" id="H4044993046"><span class="h2"><i>APOL1</i></span><span class="headingEndMark"> — </span>The increased susceptibility of Black patients to FSGS may be explained, at least in part, by genetic factors, although socioeconomic and environmental factors may also play a role.</p><p>Polymorphisms in a region of chromosome 22, which are strongly linked with African ancestry, are associated with an increased risk of developing FSGS [<a href="#rid67">67-69</a>].</p><p>Variants in the apolipoprotein L1 (<em>APOL1</em>) gene, which resides on chromosome 22, have been shown to be closely associated with nondiabetic nephropathy in Black patients [<a href="#rid70">70,71</a>]. Polymorphisms in <em>APOL1</em> appear to be expressed almost exclusively in individuals of African descent but have been less commonly identified in other populations [<a href="#rid70">70,72</a>].</p><p><em>APOL1</em> polymorphisms are associated with FSGS in Black patients:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis that compared Black patients with nonfamilial biopsy-proven FSGS to Black patients without FSGS identified two <em>APOL1</em> variants that are expressed more frequently in patients with FSGS [<a href="#rid70">70</a>]. The association of <em>APOL1</em> variants with kidney disease was confirmed in a second, larger cohort of Black patients with hypertension-associated ESKD [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>APOL1</em> genotypes were compared among 271 cases of FSGS among Black patients, 168 cases of FSGS among European American patients, and 939 control subjects [<a href="#rid73">73</a>]. <em>APOL1</em> variants conferred 17-fold higher odds (95% CI 11-26) for FSGS and 29-fold higher odds (95% CI 13-68) for HIV-associated nephropathy (HIVAN). Individuals with two <em>APOL1</em> risk alleles had an earlier age of onset and faster progression to ESKD but a similar sensitivity to glucocorticoids compared with other subjects [<a href="#rid74">74</a>]. Positive selective forces likely underlie this linkage disequilibrium, suggesting that a biological advantage is conferred by the inheritance of these variants [<a href="#rid75">75</a>]. In vitro studies suggest that the <em>APOL1</em> gene variants that predispose to kidney disease may provide superior defense against a subspecies of trypanosomes, which would provide a selective advantage to carriers of these variants against sleeping sickness [<a href="#rid70">70</a>]. (See  <a class="medical medical_review" href="/z/d/html/5697.html" rel="external">"Human African trypanosomiasis: Epidemiology, clinical manifestations, and diagnosis", section on 'Innate immunity'</a>.)</p><p></p><p>The association between <em>APOL1 </em>genotype and risk of kidney disease may be influenced by additional factors. As an example, the decline in kidney function attributed to <em>APOL1 </em>risk variants has been shown to be dependent upon plasma levels of the soluble urokinase plasminogen activator receptor (suPAR). In a study involving two independent cohorts of Black individuals (1094 patients), higher baseline suPAR levels were associated with a greater annual decline in estimated glomerular filtration rate (eGFR) among patients with two <em>APOL1 </em>risk alleles compared with those with one or no alleles [<a href="#rid76">76</a>]. This association may be explained by high-affinity protein-protein interactions between suPAR, ApoL1, and alpha v beta 3 integrin, whereby the ApoL1 protein variants G1 and G2 exhibit higher affinity for suPAR-activated alpha v beta 3 integrin than ApoL1 G0. In addition, ApoL1 G1 or G2 augment alpha v beta 3 integrin activation and cause proteinuria in mice in a suPAR-dependent manner. (See  <a class="medical medical_review" href="/z/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'suPAR'</a>.)</p><p>Screening for <em>APOL1</em> risk alleles in Black patients with FSGS lesions can confirm the association. Some experts advocate for universal screening of individuals of African ancestry with FSGS given that a clinical trial evaluating targeted therapy for <em>APOL1</em>-associated kidney disease is in progress [<a href="#rid77">77,78</a>]. (See  <a class="medical medical_review" href="/z/d/html/3100.html" rel="external">"Focal segmental glomerulosclerosis: Treatment and prognosis", section on 'Investigational therapies'</a>.)</p><p class="headingAnchor" id="H2152014668"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110250.html" rel="external">"Society guideline links: Glomerular disease in adults"</a>.)</p><p class="headingAnchor" id="H4057398799"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Focal segmental glomerulosclerosis (FSGS) can be caused by a number of genetic mutations in genes that encode for proteins expressed mainly in the podocytes and their slit diaphragm and also in other components of the glomerular filtration barrier such as the glomerular basement membrane (GBM). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology </strong>– The prevalence of genetic FSGS varies widely depending upon the population being studied. In regions of the world where consanguinity is prevalent, for example, the prevalence of genetic FSGS among all patients with FSGS may be as high as 30 percent, whereas in the outbred population, the prevalence may be as low as &lt;5 percent. (See <a class="local">'Epidemiology of genetic FSGS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation </strong>– Genetic forms of FSGS presenting in infancy or childhood typically present with full nephrotic syndrome and widespread foot process effacement on electron microscopy (EM). However, the clinical and histologic phenotype of adult-onset genetic FSGS is widely variable and rarely specific, with the same mutations showing different morphologic features on both light microscopy (LM) and EM. (See <a class="local">'Clinical presentation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications for genetic testing </strong>– The decision to obtain genetic testing depends upon the clinical presentation of the patient and the genetic architecture of disease in the population where the clinician is practicing. The use of genetic testing in the evaluation of adult patients presenting with a documented FSGS lesion on kidney biopsy and pediatric patients with glucocorticoid-resistant idiopathic nephrotic syndrome is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis", section on 'Differentiating between primary, secondary, and genetic FSGS'</a> and  <a class="medical medical_review" href="/z/d/html/117983.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Management", section on 'Genetic testing'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genes known to cause FSGS </strong>– The majority of the genetic causes of FSGS in children follow an autosomal recessive pattern of inheritance and manifest in the first year of life, with mutations in the genes for nephrin (<em>NPHS1</em>), podocin (<em>NPHS2</em>), and phospholipase C epsilon 1 (<em>PLCE1</em>) being the most common. Autosomal recessive disease is usually completely penetrant with only very rare cases of asymptomatic individuals.</p><p></p><p class="bulletIndent1">Autosomal dominant causes of FSGS are more common in older children, adolescents, and adults. The most common single-gene cause of autosomal dominant FSGS is a mutation in the gene inverted formin, FH2 and WH2 domain containin<em>g (INF2</em>). Other major genes implicated in autosomal dominant FSGS include actinin alpha <em>4 (ACTN4), TRPC6, WT1</em>, a<em>nd LMX1B</em>. </p><p></p><p class="bulletIndent1">Collagen type IV alpha 3, 4, and 5 gene mutations are increasingly recognized as the most common genetic causes of FSGS in adults. (See <a class="local">'Genes known to cause FSGS'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>FSGS in Black patients </strong>– The increased susceptibility of Black patients to FSGS may be explained, at least in part, by genetic factors although socioeconomic and environmental factors may also play a role. Variants in the apolipoprotein L1 (<em>APOL1</em>) gene have been shown to be closely associated with nondiabetic nephropathy in Black patients. Polymorphisms in <em>APOL1</em> appear to be expressed exclusively in individuals of African descent but have been less commonly identified in other populations. (See <a class="local">'FSGS in Black patients'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Sampson MG, Gillies CE, Robertson CC, et al. Using Population Genetics to Interrogate the Monogenic Nephrotic Syndrome Diagnosis in a Case Cohort. J Am Soc Nephrol 2016; 27:1970.</a></li><li><a class="nounderline abstract_t">Sadowski CE, Lovric S, Ashraf S, et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2015; 26:1279.</a></li><li><a class="nounderline abstract_t">Trautmann A, Bodria M, Ozaltin F, et al. Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort. Clin J Am Soc Nephrol 2015; 10:592.</a></li><li><a class="nounderline abstract_t">Al-Hamed MH, Al-Sabban E, Al-Mojalli H, et al. A molecular genetic analysis of childhood nephrotic syndrome in a cohort of Saudi Arabian families. J Hum Genet 2013; 58:480.</a></li><li><a class="nounderline abstract_t">Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119:e907.</a></li><li><a class="nounderline abstract_t">Barua M, Brown EJ, Charoonratana VT, et al. Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis. Kidney Int 2013; 83:316.</a></li><li><a class="nounderline abstract_t">Gbadegesin RA, Lavin PJ, Hall G, et al. Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis. Kidney Int 2012; 81:94.</a></li><li><a class="nounderline abstract_t">Lepori N, Zand L, Sethi S, et al. Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults. Clin Kidney J 2018; 11:179.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Sethi S, Nath KA, et al. Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach. J Am Soc Nephrol 2018; 29:759.</a></li><li><a class="nounderline abstract_t">Yao T, Udwan K, John R, et al. Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS. Clin J Am Soc Nephrol 2019; 14:213.</a></li><li><a class="nounderline abstract_t">Braunisch MC, Riedhammer KM, Herr PM, et al. Identification of disease-causing variants by comprehensive genetic testing with exome sequencing in adults with suspicion of hereditary FSGS. Eur J Hum Genet 2021; 29:262.</a></li><li><a class="nounderline abstract_t">Pollak MR. The genetic basis of FSGS and steroid-resistant nephrosis. Semin Nephrol 2003; 23:141.</a></li><li><a class="nounderline abstract_t">Kemper MJ, Lemke A. Treatment of Genetic Forms of Nephrotic Syndrome. Front Pediatr 2018; 6:72.</a></li><li><a class="nounderline abstract_t">Weber S, Gribouval O, Esquivel EL, et al. NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence. Kidney Int 2004; 66:571.</a></li><li><a class="nounderline abstract_t">Ruf RG, Lichtenberger A, Karle SM, et al. Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 2004; 15:722.</a></li><li><a class="nounderline abstract_t">Trautmann A, Schnaidt S, Lipska-Ziętkiewicz BS, et al. Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. J Am Soc Nephrol 2017; 28:3055.</a></li><li><a class="nounderline abstract_t">Miao J, Pinto E Vairo F, Hogan MC, et al. Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection. Mayo Clin Proc 2021; 96:2342.</a></li><li><a class="nounderline abstract_t">Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38:1397.</a></li><li><a class="nounderline abstract_t">Gellermann J, Stefanidis CJ, Mitsioni A, Querfeld U. Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations. Pediatr Nephrol 2010; 25:1285.</a></li><li><a class="nounderline abstract_t">Ashraf S, Kudo H, Rao J, et al. Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment. Nat Commun 2018; 9:1960.</a></li><li><a class="nounderline abstract_t">Heeringa SF, Chernin G, Chaki M, et al. COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness. J Clin Invest 2011; 121:2013.</a></li><li><a class="nounderline abstract_t">Ozaltin F. Primary coenzyme Q10 (CoQ 10) deficiencies and related nephropathies. Pediatr Nephrol 2014; 29:961.</a></li><li><a class="nounderline abstract_t">Ashraf S, Gee HY, Woerner S, et al. ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption. J Clin Invest 2013; 123:5179.</a></li><li><a class="nounderline abstract_t">Carraro M, Caridi G, Bruschi M, et al. Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2002; 13:1946.</a></li><li><a class="nounderline abstract_t">Pelletier JH, Kumar KR, Engen R, et al. Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings. Pediatr Nephrol 2018; 33:1773.</a></li><li><a class="nounderline abstract_t">Hickson LJ, Gera M, Amer H, et al. Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence. Transplantation 2009; 87:1232.</a></li><li><a class="nounderline abstract_t">Patrakka J, Ruotsalainen V, Reponen P, et al. Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin. Transplantation 2002; 73:394.</a></li><li><a class="nounderline abstract_t">Becker-Cohen R, Bruschi M, Rinat C, et al. Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies. Am J Transplant 2007; 7:256.</a></li><li><a class="nounderline abstract_t">Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis 2003; 41:1314.</a></li><li><a class="nounderline abstract_t">Mathis BJ, Kim SH, Calabrese K, et al. A locus for inherited focal segmental glomerulosclerosis maps to chromosome 19q13. Kidney Int 1998; 53:282.</a></li><li><a class="nounderline abstract_t">Faubert PF, Porush JG. Familial focal segmental glomerulosclerosis: nine cases in four families and review of the literature. Am J Kidney Dis 1997; 30:265.</a></li><li><a class="nounderline abstract_t">Conlon PJ, Lynn K, Winn MP, et al. Spectrum of disease in familial focal and segmental glomerulosclerosis. Kidney Int 1999; 56:1863.</a></li><li><a class="nounderline abstract_t">Winn MP, Conlon PJ, Lynn KL, et al. Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity. Genomics 1999; 58:113.</a></li><li><a class="nounderline abstract_t">Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24:251.</a></li><li><a class="nounderline abstract_t">Vats A, Nayak A, Ellis D, et al. Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13. Kidney Int 2000; 57:875.</a></li><li><a class="nounderline abstract_t">Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24:349.</a></li><li><a class="nounderline abstract_t">Vats AN, Ishwad C, Vats KR, et al. Steroid-resistant nephrotic syndrome and congenital anomalies of kidneys: evidence of locus on chromosome 13q. Kidney Int 2003; 64:17.</a></li><li><a class="nounderline abstract_t">Kitamura A, Tsukaguchi H, Iijima K, et al. Genetics and clinical features of 15 Asian families with steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 2006; 21:3133.</a></li><li><a class="nounderline abstract_t">Caridi G, Bertelli R, Carrea A, et al. Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 2001; 12:2742.</a></li><li><a class="nounderline abstract_t">Brown EJ, Schlöndorff JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42:72.</a></li><li><a class="nounderline abstract_t">Boyer O, Benoit G, Gribouval O, et al. Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22:239.</a></li><li><a class="nounderline abstract_t">Santín S, Bullich G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6:1139.</a></li><li><a class="nounderline abstract_t">Philippe A, Nevo F, Esquivel EL, et al. Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome. J Am Soc Nephrol 2008; 19:1871.</a></li><li><a class="nounderline abstract_t">Santín S, García-Maset R, Ruíz P, et al. Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis. Kidney Int 2009; 76:1268.</a></li><li><a class="nounderline abstract_t">Fuchshuber A, Mehls O. Familial steroid-resistant nephrotic syndromes: recent advances. Nephrol Dial Transplant 2000; 15:1897.</a></li><li><a class="nounderline abstract_t">Tory K, Menyhárd DK, Woerner S, et al. Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome. Nat Genet 2014; 46:299.</a></li><li><a class="nounderline abstract_t">Tsukaguchi H, Sudhakar A, Le TC, et al. NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele. J Clin Invest 2002; 110:1659.</a></li><li><a class="nounderline abstract_t">Weins A, Kenlan P, Herbert S, et al. Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis. J Am Soc Nephrol 2005; 16:3694.</a></li><li><a class="nounderline abstract_t">Henderson JM, Alexander MP, Pollak MR. Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury. J Am Soc Nephrol 2009; 20:961.</a></li><li><a class="nounderline abstract_t">Reiser J, Polu KR, Möller CC, et al. TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 2005; 37:739.</a></li><li><a class="nounderline abstract_t">Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308:1801.</a></li><li><a class="nounderline abstract_t">Santín S, Ars E, Rossetti S, et al. TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis. Nephrol Dial Transplant 2009; 24:3089.</a></li><li><a class="nounderline abstract_t">Schlöndorff J, Del Camino D, Carrasquillo R, et al. TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription. Am J Physiol Cell Physiol 2009; 296:C558.</a></li><li><a class="nounderline abstract_t">Malone AF, Phelan PJ, Hall G, et al. Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis. Kidney Int 2014; 86:1253.</a></li><li><a class="nounderline abstract_t">Gast C, Pengelly RJ, Lyon M, et al. Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis. Nephrol Dial Transplant 2016; 31:961.</a></li><li><a class="nounderline abstract_t">Xie J, Wu X, Ren H, et al. COL4A3 mutations cause focal segmental glomerulosclerosis. J Mol Cell Biol 2014; 6:498.</a></li><li><a class="nounderline abstract_t">Sen ES, Dean P, Yarram-Smith L, et al. Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations. J Med Genet 2017; 54:795.</a></li><li><a class="nounderline abstract_t">Yao XD, Chen X, Huang GY, et al. Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis. Orphanet J Rare Dis 2012; 7:100.</a></li><li><a class="nounderline abstract_t">Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science 2003; 300:1298.</a></li><li><a class="nounderline abstract_t">Boyer O, Woerner S, Yang F, et al. LMX1B mutations cause hereditary FSGS without extrarenal involvement. J Am Soc Nephrol 2013; 24:1216.</a></li><li><a class="nounderline abstract_t">Haas M, Meehan SM, Karrison TG, Spargo BH. Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997. Am J Kidney Dis 1997; 30:621.</a></li><li><a class="nounderline abstract_t">Korbet SM, Genchi RM, Borok RZ, Schwartz MM. The racial prevalence of glomerular lesions in nephrotic adults. Am J Kidney Dis 1996; 27:647.</a></li><li><a class="nounderline abstract_t">Abbott KC, Hypolite I, Welch PG, Agodoa LY. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol 2001; 14:377.</a></li><li><a class="nounderline abstract_t">Freedman BI, Soucie JM, Stone SM, Pegram S. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis 1999; 34:254.</a></li><li><a class="nounderline abstract_t">Fogo A, Breyer JA, Smith MC, et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int 1997; 51:244.</a></li><li><a class="nounderline abstract_t">Toto RD. Proteinuria and hypertensive nephrosclerosis in African Americans. Kidney Int Suppl 2004; :S102.</a></li><li><a class="nounderline abstract_t">Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet 2008; 40:1175.</a></li><li><a class="nounderline abstract_t">Pollak MR. Kidney disease and African ancestry. Nat Genet 2008; 40:1145.</a></li><li><a class="nounderline abstract_t">Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.</a></li><li><a class="nounderline abstract_t">Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010; 329:841.</a></li><li><a class="nounderline abstract_t">Genovese G, Tonna SJ, Knob AU, et al. A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9. Kidney Int 2010; 78:698.</a></li><li><a class="nounderline abstract_t">Nadkarni GN, Gignoux CR, Sorokin EP, et al. Worldwide Frequencies of APOL1 Renal Risk Variants. N Engl J Med 2018; 379:2571.</a></li><li><a class="nounderline abstract_t">Kopp JB, Nelson GW, Sampath K, et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22:2129.</a></li><li><a class="nounderline abstract_t">Kopp JB, Winkler CA, Zhao X, et al. Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015; 26:1443.</a></li><li><a class="nounderline abstract_t">Freedman BI, Kopp JB, Langefeld CD, et al. The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans. J Am Soc Nephrol 2010; 21:1422.</a></li><li><a class="nounderline abstract_t">Hayek SS, Koh KH, Grams ME, et al. A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease. Nat Med 2017; 23:945.</a></li><li><a class="nounderline abstract_t">Gbadegesin R, Lane B. Inaxaplin for the treatment of APOL1-associated kidney disease. Nat Rev Nephrol 2023; 19:479.</a></li><li><a class="nounderline abstract_t">Egbuna O, Zimmerman B, Manos G, et al. Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants. N Engl J Med 2023; 388:969.</a></li></ol></div><div id="topicVersionRevision">Topic 117559 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26534921" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Using Population Genetics to Interrogate the Monogenic Nephrotic Syndrome Diagnosis in a Case Cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25349199" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635037" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Spectrum of steroid-resistant and congenital nephrotic syndrome in children: the PodoNet registry cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23595123" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A molecular genetic analysis of childhood nephrotic syndrome in a cohort of Saudi Arabian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17371932" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Nephrotic syndrome in the first year of life: two thirds of cases are caused by mutations in 4 genes (NPHS1, NPHS2, WT1, and LAMB2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014460" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Mutations in the INF2 gene account for a significant proportion of familial but not sporadic focal and segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21866090" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Inverted formin 2 mutations with variable expression in patients with sporadic and hereditary focal and segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29644057" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29321142" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30647093" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Integration of Genetic Testing and Pathology for the Diagnosis of Adults with FSGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32887937" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Identification of disease-causing variants by comprehensive genetic testing with exome sequencing in adults with suspicion of hereditary FSGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12704574" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The genetic basis of FSGS and steroid-resistant nephrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29632851" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of Genetic Forms of Nephrotic Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15253708" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : NPHS2 mutation analysis shows genetic heterogeneity of steroid-resistant nephrotic syndrome and low post-transplant recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14978175" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28566477" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34120753" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Identification of Genetic Causes of Focal Segmental Glomerulosclerosis Increases With Proper Patient Selection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17086182" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20191369" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Successful treatment of steroid-resistant nephrotic syndrome associated with WT1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773874" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mutations in six nephrosis genes delineate a pathogenic pathway amenable to treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21540551" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : COQ6 mutations in human patients produce nephrotic syndrome with sensorineural deafness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23736673" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Primary coenzyme Q10 (CoQ 10) deficiencies and related nephropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270420" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : ADCK4 mutations promote steroid-resistant nephrotic syndrome through CoQ10 biosynthesis disruption.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12089392" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Serum glomerular permeability activity in patients with podocin mutations (NPHS2) and steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29982878" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Recurrence of nephrotic syndrome following kidney transplantation is associated with initial native kidney biopsy findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384172" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Kidney transplantation for primary focal segmental glomerulosclerosis: outcomes and response to therapy for recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11884936" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Recurrence of nephrotic syndrome in kidney grafts of patients with congenital nephrotic syndrome of the Finnish type: role of nephrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17109732" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Recurrent nephrotic syndrome in homozygous truncating NPHS2 mutation is not due to anti-podocin antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12776285" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Recurrence of focal segmental glomerulosclerosis after renal transplantation in patients with mutations of podocin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9461087" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A locus for inherited focal segmental glomerulosclerosis maps to chromosome 19q13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9261039" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Familial focal segmental glomerulosclerosis: nine cases in four families and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10571795" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Spectrum of disease in familial focal and segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10368108" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Linkage of a gene causing familial focal segmental glomerulosclerosis to chromosome 11 and further evidence of genetic heterogeneity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10700177" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Mutations in ACTN4, encoding alpha-actinin-4, cause familial focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10720940" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Familial nephrotic syndrome: clinical spectrum and linkage to chromosome 19q13.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10742096" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787391" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Steroid-resistant nephrotic syndrome and congenital anomalies of kidneys: evidence of locus on chromosome 13q.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968734" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genetics and clinical features of 15 Asian families with steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11729243" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20023659" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258034" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Mutations in INF2 are a major cause of autosomal dominant focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21415313" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614772" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Nephrin mutations can cause childhood-onset steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19812541" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nephrin mutations cause childhood- and adult-onset focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096125" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Familial steroid-resistant nephrotic syndromes: recent advances.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24509478" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutation-dependent recessive inheritance of NPHS2-associated steroid-resistant nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12464671" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251236" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Mutational and Biological Analysis of alpha-actinin-4 in focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19357256" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Patients with ACTN4 mutations demonstrate distinctive features of glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15924139" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15879175" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458060" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : TRPC6 mutational analysis in a large cohort of patients with focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19129465" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : TRPC6 mutations associated with focal segmental glomerulosclerosis cause constitutive activation of NFAT-dependent transcription.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25229338" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Rare hereditary COL4A3/COL4A4 variants may be mistaken for familial focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26346198" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Collagen (COL4A) mutations are the most frequent mutations underlying adult focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596306" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : COL4A3 mutations cause focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28780565" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Clinical genetic testing using a custom-designed steroid-resistant nephrotic syndrome gene panel: analysis and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23259488" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Challenge in pathologic diagnosis of Alport syndrome: evidence from correction of previous misdiagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764198" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687361" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : LMX1B mutations cause hereditary FSGS without extrarenal involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9370176" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Changing etiologies of unexplained adult nephrotic syndrome: a comparison of renal biopsy findings from 1976-1979 and 1995-1997.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8629623" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : The racial prevalence of glomerular lesions in nephrotic adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11730270" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10430971" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995739" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15485398" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Proteinuria and hypertensive nephrosclerosis in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794856" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18818713" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Kidney disease and African ancestry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18794854" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : MYH9 is associated with nondiabetic end-stage renal disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647424" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Association of trypanolytic ApoL1 variants with kidney disease in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20668430" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : A risk allele for focal segmental glomerulosclerosis in African Americans is located within a region containing APOL1 and MYH9.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586505" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Worldwide Frequencies of APOL1 Renal Risk Variants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21997394" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25573908" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical Features and Histology of Apolipoprotein L1-Associated Nephropathy in the FSGS Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20688934" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The apolipoprotein L1 (APOL1) gene and nondiabetic nephropathy in African Americans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28650456" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : A tripartite complex of suPAR, APOL1 risk variants andαvβ3 integrin on podocytes mediates chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37106136" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Inaxaplin for the treatment of APOL1-associated kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36920755" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
